Multidrug-resistant North American pulsotype 2 clostridium difficile was the predominant toxigenic hospital-acquired strain in the province of Manitoba, Canada, in 2006-2007

Journal of Medical Microbiology

Volumn 61, Issue 5, 2012, Pages 693-700

  Karlowsky, James A ^a,b   Zhanel, George G ^a   Hammond, Greg W ^a   Rubinstein, Ethan ^a   Wylie, John ^a,c   Du, Tim ^d   Mulvey, Michael R ^a,d   Alfa, Michelle J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Diagnostic Services of Manitoba Inc   (Canada)

^c CADHAM PROVINCIAL LABORATORY   (Canada)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; CLINDAMYCIN; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CANADA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; HEREDITY; MULTIDRUG RESISTANCE; NONHUMAN; NORTH AMERICAN PULSOTYPE 2; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; HUMANS; MANITOBA; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; WISKOTT-ALDRICH SYNDROME PROTEIN;

EID: 84859836905     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.041053-0     Document Type: Article

References (30)

1. al-Barrak, A., Embil, J., Dyck, B., Olekson, K., Nicoll, D., Alfa, M. J. & Kabani, A. (1999). An outbreak of toxin A negative, toxin B positive Clostridium difficile-associated diarrhea in a Canadian tertiary-care hospital. Can Commun Dis Rep 25, 65-69.
2. Alfa, M. J., Kabani, A., Lyerly, D., Moncrief, S., Neville, L. M., Al- Barrak, A., Harding, G. K., Dyck, B., Olekson, K. & Embil, J. M. (2000). Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol 38, 2706-2714.
3. Bidet, P., Lalande, V., Salauze, B., Burghoffer, B., Avesani, V., Delmée, M., Rossier, A., Barbut, F. & Petit, J.-C. (2000). Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile. J Clin Microbiol 38, 2484-2487.
4. Bourgault, A.-M., Lamothe, F., Loo, V. G., Poirier, L. and CDAD-CSI Study Group (2006). In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada. Antimicrob Agents Chemother 50, 3473-3475.
5. CLSI (2007). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria, 7th edn. Approved standard M11-A7. Wayne, PA: National Committee for Clinical Laboratory Standards.
6. Hospital Infection Control Practices Advisory Committee (1995). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 16, 105-113.
7. Hubert, B., Loo, V. G., Bourgault, A. M., Poirier, L., Dascal, A., Fortin, E., Dionne, M. & Lorange, M. (2007). A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec. Clin Infect Dis 44, 238-244.
8. Johnson, E. A., Summanen, P. & Finegold, S. M. (2007). Clostridium. In Manual of Clinical Microbiology, vol. 1, pp. 889-910. Edited by P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry & M. A. Pfaller. Washington, DC: American Society for Microbiology.
9. Kato, H., Kato, N., Watanabe, K., Iwai, N., Nakamura, H., Yamamoto, T., Suzuki, K., Kim, S.-M., Chong, Y. & Wasito, E. B. (1998). Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol 36, 2178-2182.
10. Kelly, C. P. & LaMont, J. T. (2008). Clostridium difficile - more difficult than ever. N Engl J Med 359, 1932-1940.
11. Killgore, G., Thompson, A., Johnson, S., Brazier, J., Kuijper, E., Pepin, J., Frost, E. H., Savelkoul, P., Nicholson, B. & other authors (2008). Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. J Clin Microbiol 46, 431-437.
12. Lambert, P. J., Dyck, M., Thompson, L. H. & Hammond, G. W. (2009). Population-based surveillance of Clostridium difficile infection in Manitoba, Canada, by using interim surveillance definitions. Infect Control Hosp Epidemiol 30, 945-951.
13. Lemee, L., Dhalluin, A., Testelin, S., Mattrat, M.-A., Maillard, K., Lemeland, J.-F. & Pons, J.-L. (2004). Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (toxin A), and tcdB (toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol 42, 5710-5714.
14. Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C. & other authors (2005). A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353, 2442-2449.
15. MacCannell, D. R., Louie, T. J., Gregson, D. B., Laverdiere, M., Labbe, A.-C., Laing, F. & Henwick, S. (2006). Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol 44, 2147-2152.
16. Martin, H., Willey, B., Low, D. E., Staempfli, H. R., McGeer, A., Boerlin, P., Mulvey, M. & Weese, J. S. (2008). Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006. J Clin Microbiol 46, 2999-3004.
17. Matamouros, S., England, P. & Dupuy, B. (2007). Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol 64, 1274-1288.
18. McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Jr, Kazakova, S. V., Sambol, S. P., Johnson, S. & Gerding, D. N. (2005). An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353, 2433-2441.
19. McDonald, L. C., Owings, M. & Jernigan, D. B. (2006). Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 12, 409-415.
20. McDonald, L. C., Coignard, B., Dubberke, E., Song, X., Horan, T., Kutty, P. K. & Ad Hoc Clostridium difficile Surveillance Working Group (2007). Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 28, 140-145.
21. Miller, M., Gravel, D., Mulvey, M., Taylor, G., Boyd, D., Simor, A., Gardam, M., McGeer, A., Hutchinson, J. & other authors (2010). Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 50, 194-201.
22. Murray, R., Boyd, D., Levett, P. N., Mulvey, M. R. & Alfa, M. J. (2009). Truncation in the tcdC region of the Clostridium difficile PathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin A. BMC Infect Dis 9, 103.
23. Musher, D. M., Aslam, S., Logan, N., Nallacheru, S., Bhaila, I., Borchert, F. & Hamill, R. J. (2005). Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40, 1586-1590.
24. Pepin, J., Alary, M. E., Valiquette, L., Raiche, E., Ruel, J., Fulop, K., Godin, D. & Bourassa, C. (2005). Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 40, 1591-1597.
25. Rodriguez-Palacios, A., Reid-Smith, R. J., Staempfli, H. R., Daignault, D., Janecko, N., Avery, B. P., Martin, H., Thomspon, A. D., McDonald, L. C. & other authors (2009). Possible seasonality of Clostridium difficile in retail meat, Canada. Emerg Infect Dis 15, 802-805.
26. Spigaglia, P. & Mastrantonio, P. (2002). Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol 40, 3470-3475.
27. Stubbs, S., Rupnik, M., Gibert, M., Brazier, J., Duerden, B. & Popoff, M. (2000). Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 186, 307-312.
28. Visser, M., Sepehri, S., Olson, N., Du, T., Mulvey, M. R. &Alfa, M. J. (2012). Detection of Clostridium difficile in retail ground meat products in Manitoba, Canada. Can J Infect Dis Med Microbiol (in press).
29. Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., Frost, E. & McDonald, L. C. (2005). Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366, 1079-1084.
30. Werner, N. L., Hecker, M. T., Sethi, A. K. & Donskey, C. J. (2011). Unnecessary use of fluoroquinolone antibiotics in hospitalized patients. BMC Infect Dis 11, 187.